CCK Activators
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-71623 | 130408-77-4 | sc-203487 | 1 mg | $284.00 | 1 | |
A-71623 is distinguished by its role as a cholecystokinin (CCK) receptor agonist, engaging in specific molecular interactions that activate signaling pathways associated with digestive processes. Its unique structural conformation allows for high affinity binding to CCK receptors, influencing downstream effects on enzyme secretion and gastrointestinal motility. The compound's dynamic interaction with lipid membranes enhances its bioavailability, while its stability under physiological conditions supports sustained receptor activation. | ||||||
Gastrin-1, rat | 81123-06-0 | sc-397105 | 0.5 mg | $337.00 | ||
Gastrin-1, rat, functions as a potent stimulator of gastric acid secretion, engaging with specific receptors in the gastric mucosa. Its unique peptide structure facilitates interactions with the CCK-B receptor, triggering intracellular signaling cascades that enhance gastric motility and enzyme release. The compound exhibits rapid kinetics in receptor binding, leading to swift physiological responses. Additionally, its stability in the gastrointestinal environment ensures effective modulation of digestive processes. | ||||||
Devazepide | 103420-77-5 | sc-203562 sc-203562A | 5 mg 50 mg | $245.00 $1030.00 | 1 | |
A potent and selective antagonist of the CCK-A receptor, devazepide can indirectly increase CCK activity by blocking inhibitory feedback mechanisms. | ||||||
Proglumide | 6620-60-6 | sc-460085 sc-460085A | 1 g 25 g | $320.00 $681.00 | ||
Proglumide, a non-selective CCK receptor antagonist, can indirectly promote CCK activity by reducing competitive inhibition at its receptors. | ||||||
Famotidine | 76824-35-6 | sc-205691 sc-205691A | 500 mg 1 g | $65.00 $111.00 | ||
Famotidine, another H2 receptor antagonist, can indirectly promote CCK activity by reducing gastric acid secretion, thus influencing CCK release. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Cimetidine, a histamine H2 receptor antagonist, can enhance CCK secretion indirectly by modulating gastric acid levels, which are closely related to CCK activity. | ||||||
Ranitidine | 66357-35-5 | sc-203679 | 1 g | $193.00 | ||
As an H2 receptor antagonist, ranitidine can indirectly increase CCK activity through its effects on gastric acid secretion, which affects CCK release. | ||||||
Nizatidine | 76963-41-2 | sc-205771 sc-205771A | 5 g 10 g | $72.00 $140.00 | ||
Nizatidine, another H2 receptor antagonist, may indirectly stimulate CCK activity by influencing gastric acid levels, thereby affecting CCK secretion. | ||||||
Roxatidine | 78273-80-0 | sc-280071A sc-280071 | 1 mg 10 mg | $61.00 $459.00 | 1 | |
Roxatidine, an H2 receptor antagonist, indirectly enhances CCK activity by modulating gastric acid secretion, a process that is linked to CCK release. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Omeprazole, a proton pump inhibitor, can indirectly increase CCK activity by altering gastric acid secretion, which plays a role in CCK regulation. | ||||||